Fritextsökning
Artiklar per år
Innehållstyper
-
Nytt nummer – Biotechbolagens fantasifulla namn och intervju med sjukvårdsministern
Nu är ett nytt nummer av Life Science Sweden skickat till tryck. Där läser du bland annat en intervju sjukvårdsministern Acko Ankarberg Johansson. Från och med det nya numret har tidningen både ny form och nytt format.
-
Efterlängtat vaccin mot RS-virus nu godkänt i USA
Det första vaccinet mot RS-virus har godkänts i USA för personer som är 60 år och äldre.
-
Han är Swedish Labtechs nya ordförande
Branschorganisationen Swedish Labtech har nu valt en ny ordförande. Det blir Mattias Bengtsson som tar över stafettpinnen efter Peter Simonsbacka.
-
Uncertainty about the government’s life science work
The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now questions are being raised both about the government’s plans for the office and the Swedish life science strategy.
-
Pfizer’s record year – topped the $100 billion mark
In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson as the industry’s top selling business.
-
He got inside the head of Sweden’s vaccine hunter
The hunt for the COVID-19 vaccine is the theme of the new book Vaccinjägaren (The Vaccine Hunter). It tells the story of Richard Bergström’s mission as Sweden’s national vaccine coordinator and the scheming that went on behind the scenes in Europe
-
Pfizers rekordår – sprängde 100 miljardersvallen
Pfizer lyckades i fjol, som första läkemedelsbolag i historien, sälja för över 100 miljarder dollar under ett år. Det visar en sammanställning över företagen med de största intäkterna inom läkemedelsindustrin.
-
Life science-profil lämnar vd-jobbet i Umeå
Jennie Ekbeck, vd för Umeå Biotech Incubator (UBI), lämnar sin post efter 11 år. "Jag har nu kommit fram till att det är dags att göra något annat. Vad det är har jag ingen aning om, men framtiden känns väldigt spännande", skriver hon på Linkedin.
-
The impact of the recession on the Swedish medtech sector
We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.
-
Konkurrenskraftig klinisk forskning mål för ny utredning
Alf-avtalet står i fokus när regeringen nu tillsätter en ny utredning med syfte att lägga fram ett underlag inför en omförhandling av avtalet.
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage during a webcast seminar.
-
Swelife: Nu krävs gemensamma krafttag för svensk life science
DEBATT: Efter årsskiftet har life science-frågorna hamnat i skymundan för andra frågor på den politiska agendan. Det är viktigt att vi inte tappar den framdrift som hela sektorn fick med en nationell life science-samordnare, ett life science-kontor och en nationell life science-strategi. Handen på hjärtat, vem äger life science-frågan?
-
Column: ”Cheating with pea flowers and does it matter whether you are right?”
Is it possible to forgive shortcuts or outright cheating in science - if it turns out that the researcher was ultimately right? Anna Törner discuss this topic in a column.
-
”Ärtfusk och spelar det någon roll om man har rätt?”
Går det att förlåta genvägar eller rent av fusk inom vetenskap – om det visar sig att forskaren i slutändan hade rätt? Om det resonerar Anna Törner i en krönika.
-
The Swedish National Board of Health and Welfare rejects prioritising andrology as a speciality
Male infertility can be linked to a shorter lifespan and several severe diseases, but when couples who want children are examined, the focus is on the woman. Experts in the field claim that andrology needs to become a speciality in Sweden to increase awareness and knowledge. But the Swedish National Board of Health and Welfare says that it is not a priority.
-
“An entire industry is about to be wiped out”
According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden speaks to believe that the results must be taken seriously, and call for action from the Swedish authorities.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing writes in a column.
-
A surprising discovery about the immune system in cases of cancer
Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising discovery about the function of the immune system.
-
Claims of life science companies fleeing abroad is a myth according to survey
The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.
-
The government proposes fines for pharmaceutical companies that fail to notify drug shortages in time
According to a compilation from the Swedish Medicines Agency, the number of residually notified medicines increased by 54 % in Sweden last year compared to the previous year. In a bill presented by the government a number of proposals are put forward to counteract the problem.
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the availability of medical devices in the EU. Unfortunately, the fears have come true.
-
Sweden is organising a large life science conference as part of the EU presidency
On 26-27 June, Sweden will host a European meeting on life science.
-
“Everyone is screaming for talent”
Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Horizons in Biologics & Bioprocessing conference on 15 December.
BREAKING